Journal of Thoracic Oncology最新文献

Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer. 新出现的靶向治疗her2突变非小细胞肺癌。

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-02 DOI: 10.1016/j.jtho.2026.103899

Benedetta Del Rio, Silvia Masini, Camilo Cáceres-Galvis, Javier Torres-Jiménez, Helena Bote, María Zurera, Javier Baena, Cristina Serrano, Juan Antonio Nuñez, Santiago Ponce-Aix, Luis Paz-Ares, Jon Zugazagoitia

{"title":"Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.","authors":"Benedetta Del Rio, Silvia Masini, Camilo Cáceres-Galvis, Javier Torres-Jiménez, Helena Bote, María Zurera, Javier Baena, Cristina Serrano, Juan Antonio Nuñez, Santiago Ponce-Aix, Luis Paz-Ares, Jon Zugazagoitia","doi":"10.1016/j.jtho.2026.103899","DOIUrl":"https://doi.org/10.1016/j.jtho.2026.103899","url":null,"abstract":"<p><p>HER2-mutant lung cancer represents approximately 2-5% of all NSCLCs and is associated with poor prognosis. Two different HER2-targeted therapeutic approaches with different mechanisms of action -antibody-drug conjugates (ADCs) and HER2-selective tyrosine-kinase inhibitors (TKIs)- have shown convincing efficacy in pretreated patients. Trastuzumab deruxtecan (T-DXd) was the first targeted therapy approved for patients with HER2-mutant NSCLC, demonstrating robust and durable responses in about 50% of these patients. Toxicity, while overall manageable, includes an increased risk of interstitial lung disease (ILD), which can be problematic and requires close clinical monitoring. More novel HER2-directed ADCs have confirmed the solid efficacy in this tumor type, showing variable rates of ILD as a class effect of these agents. On the other hand, novel orally available TKIs with higher specificity and inhibitory potency against HER2 over wild type EGFR such as sevabertinib (a dual HER2/EGFR mutant-selective reversible TKI) or zongertinib (an irreversible HER2-selective TKI that spares EGFR, including mutant EGFR) have further demonstrated deep and durable responses in this disease. Toxicities with these agents are mostly related to EGFR wild type inhibition, with significantly lower rates of ILD. Consistent with its selectivity and mechanism of action, zongertinib offers a favorable tolerability profile, with mainly low-grade adverse events including those related to wild type EGFR inhibition. In this review, we first describe the molecular landscape and clinical features of HER2-mutant NSCLC. Then, we summarize the clinical and preclinical evidence of HER2-targeted therapies and provide a forward-looking perspective of the treatment landscape of HER2-mutant NSCLC.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":"103899"},"PeriodicalIF":20.8,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PP01.26: Prediction of Overall Survival in Metastatic Non-Small Cell Lung Cancer Patients: A SEER Population–Based Cohort Study PP01.26：转移性非小细胞肺癌患者总生存率的预测：一项基于SEER人群的队列研究

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103769

Kang Qin , An. Qin

引用次数: 0

Tobacco News Update—From the IASLC Tobacco Control Committee 烟草新闻更新-来自IASLC烟草控制委员会

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-08 DOI: 10.1016/j.jtho.2026.103690

引用次数: 0

PP01.65: Real-World Experience of Afatinib as First Line Treatment in Advanced NSCLC with Exon 19 Deletion and Exon 21 L858R Mutations as a Cheaper Alternative to Osimertinib in an LMIC Setting: A Single Institutional Study PP01.65：一项单一机构研究：阿法替尼作为LMIC环境中奥西替尼更便宜的替代方案，在具有外显子19缺失和外显子21 L858R突变的晚期NSCLC一线治疗的实际经验

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103808

Dr. Anupam Datta , Dr. Soumita Majumder

引用次数: 0

PP01.95: Real-World EGFR Testing and Adjuvant Treatment Patterns Among Patients with Resected Early-Stage Non-Small Cell Lung Cancer (NSCLC) in the United States PP01.95：美国早期非小细胞肺癌（NSCLC）患者的真实世界EGFR检测和辅助治疗模式

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103832

Furaha Kariburyo-Yay , Yi Liang , Daniel Simmons , Vincent Miller , Joanna Pye , Gregory Ursino

引用次数: 0

PP01.96: A Propensity-Matched Analysis on the Short- and Long-Term Outcomes of High-Risk Lung Resections for NSCLC PP01.96：高风险非小细胞肺癌肺切除术短期和长期结果的倾向匹配分析

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103833

Pablo Gomes-da Silva de Rosenzweig, Yahya Saif, Hannah Jesani, Hasnali David Walji, Antonio Martin-Ucar, Luis Hernandez

引用次数: 0

PP01.17: Challenges to Providing Optimal Multidisciplinary Care in Resectable Non-Small Cell Lung Cancer in the United States: A Healthcare Provider Best-Worst Scaling Survey PP01.17：在美国为可切除的非小细胞肺癌提供最佳多学科护理的挑战：一项医疗保健提供者最佳最差尺度调查

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103760

Daniel Simmons , William Wang , Kathryn Krupsky , David Cornwall , Kathleen Beusterien , Emily Mulvihill , Corey Neff , Melody Hughes , Tiernan Mulrooney , Nicholas Theilen , Debora Bruno

引用次数: 0

PP01.53: Detection of EGFR T790M by Digital PCR: Experience in Resource-Limited Settings PP01.53：数字PCR检测EGFR T790M：在资源有限的环境下的经验

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103796

Rabiga Kadyrbayeva , Dilyara Kaidarova , Madina Orazgalieva , Saniya Ossikbayeva , Innara Turkpenova

引用次数: 0

PP01.62: Challenges in the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Small Cell Transformation and a Novel FAM120B-ALK Fusion Partner PP01.62: alk重排非小细胞肺癌治疗的挑战：小细胞转化和新的FAM120B-ALK融合伙伴

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-05-07 DOI: 10.1016/j.jtho.2026.103805

Srichandhana Rajamouli , Ryan Nguyen , Frank Weinberg , Noor Naffakh , Aseem Aseem , Anu Chundury , Matthew Harkenrider , Nan Sethakorn , Kathleen Kennedy

引用次数: 0

Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee 国际肺癌罕见肿瘤研究协会胸腺肿瘤小组委员会胸腺上皮肿瘤诊断和治疗的挑战和争议。

IF 20.8 1区医学

Journal of Thoracic Oncology Pub Date : 2026-05-01 Epub Date: 2026-04-10 DOI: 10.1016/j.jtho.2026.103611

Fatemeh Ardeshir-Larinani MD, MSc , Leanne Ashrafian MD, PhD , Marco Chiappetta MD , Daniel Mansilla MD , Alessandro Wasum Mariani MD, PhD , Jessica Menis MD , Andreas Rimner MD , Aparna Sharma MD , Malgorzata Szolkowska MD, PhD , Swasthik Upadhya MD , Jeffrey B. Velotta MD , Ioannis Vlahos MD , Chunwei Xu MD, PhD , Aaron S. Mansfield MD , Paul Baas MD, PhD , Anja C. Roden MD

{"title":"Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee","authors":"Fatemeh Ardeshir-Larinani MD, MSc , Leanne Ashrafian MD, PhD , Marco Chiappetta MD , Daniel Mansilla MD , Alessandro Wasum Mariani MD, PhD , Jessica Menis MD , Andreas Rimner MD , Aparna Sharma MD , Malgorzata Szolkowska MD, PhD , Swasthik Upadhya MD , Jeffrey B. Velotta MD , Ioannis Vlahos MD , Chunwei Xu MD, PhD , Aaron S. Mansfield MD , Paul Baas MD, PhD , Anja C. Roden MD","doi":"10.1016/j.jtho.2026.103611","DOIUrl":"10.1016/j.jtho.2026.103611","url":null,"abstract":"<div><div>Thymic epithelial tumors (TETs), comprising thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms, are rare prevascular (anterior) mediastinal malignancies characterized by histologic and clinical heterogeneity. Their management is complex because of overlapping pathologic features, variable clinical behavior, frequent associations with autoimmune conditions, and lack of standardized therapeutic algorithms. This review addresses current challenges across the diagnosis, management, and treatment of TETs. We outline diagnostic difficulties, including distinguishing TETs from histologic mimickers, and highlight the utility of immunohistochemical and molecular markers. Surgical considerations for early-stage disease are explored, debating thymomectomy versus complete thymectomy and optimal minimally invasive approaches, while also discussing the role of lymph node dissection and adjuvant therapy. Furthermore, this review delves into the evolving roles of immunotherapy and targeted therapy in TETs, acknowledging their potential while addressing challenges such as high rates of autoimmune disease recurrence and adverse events. The promising, albeit largely retrospective, applications of artificial intelligence in TETs, spanning diagnosis, target discovery, and prognostic modeling, are also explored as a critical area for future integration into clinical practice.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"21 5","pages":"Article 103611"},"PeriodicalIF":20.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0